We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





NGeneBio Showcases NGS-Based Oncology/Genetic Diseases Kits and NGenePlex nCoV qRT-PCR Kit Against COVID-19

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Image: NGenePlex nCoV qRT-PCR Kit (Photo courtesy of NGeneBio)
Image: NGenePlex nCoV qRT-PCR Kit (Photo courtesy of NGeneBio)

NGeneBio (Seoul, Korea) showcased its next-generation sequencing (NGS)-based oncology/genetic diseases kits and NGenePlex nCoV qRT-PCR kit against COVID-19 at AACC 2021.

Dedicated to achieving better health through laboratory medicine, the American Association for Clinical Chemistry, AACC, brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science.

At AACC 2021, NGeneBio showcased its NGS-based oncology/genetic diseases kits (BRCA/HEME/SOLID/ONCO/HLA). NGeneBio’s BRCAaccuTest and BRCAaccuTest PLUS are a reagent kit for producing libraries for analyzing the BRCA1 and BRCA2 genes using the NGS method, which analyzes genomic DNA derived from blood or FFPE tissue. The kit is intended for breast and ovarian cancer patients, HBOC (Hereditary breast and ovarian cancer syndrome) patients, and for family history or the age of breast cancer incidence.

Also on display at the event were NGeneBio’s HEMEaccuTest for molecular genetic test of multiple genes related hematologic malignancy; SOLIDaccuTest to explorer variants associated with solid tumors using a comprehensive method of NGS; HLAaccuTest All which is an in vitro diagnostic medical device for HLA (human leukocyte antigen) typing that can identify high-resolution histocompatibility antigens using NGS; and ONCOaccuPanel, a comprehensive solid tumor oncology NGS test.

In addition, NGeneBio demonstrated its NGeneAnalySys software for analysis of the genetic testing data produced by NGS and helps to report in clinical-grade for oncology test, alongside the EasyHLAanalyzer which provides the HLA typing identifying human leukocyte antigen for histocompatibility antigens using data from NGS. Also on display at AACC 2021 was NGeneBio’s NGenePlex nCoV qRT-PCR Kit which is a reagent of real-time reverse transcription-polymerase chain reaction (RT-PCR) assay intended for the qualitatively detecting nucleic acid of SARS-CoV-2 from patients infected or suspected of COVID-19.

Related Links:
NGeneBio 

New
Gold Supplier
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
New
Automatic Chemistry Analyzer
DS301
New
Anti-HIV 1/2 ELISA Test
HIV 1/2 Antibody (3rd) Test Kit (ELISA)
New
Infliximab Immunoassay
RIDASCREEN IFX Monitoring

Print article
AACC
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: Mindray ToRCH reagents deliver excellent seroconversion sensitivity (Photo courtesy of Mindray)

Mindray Launches High-Sensitivity and High-Specificity ToRCH Panel

Mindray (Shenzhen, China) has launched the ToRCH Panel that provides high-quality assays to meet different clinical needs. Thanks to the improved raw materials, processes, formulas, reaction models, and... Read more

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.